The emerging role of lymphocyte‐activation gene 3 targeting in the treatment of solid malignancies

Checkpoint inhibitors targeting the lymphocyte-activation gene 3 (LAG-3) pathway in combination with PD-1 blockade aim to provide similar efficacy and reduced toxicity than that of dual PD-1/CTLA-4 i…

Read the full article here

Related Articles